SCHEMBL4281402

SCHEMBL4281402

O=S(=O)(c1cccc(Cl)c1)N(C1CC1)C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 11/20 0.49
HTR2A P28223 3/20 0.45
HTR2C P28335 3/20 0.45
HTR1A P08908 2/20 0.44
ADRB3 P13945 2/20 0.44
DRD2 P14416 2/20 0.44
ADRA2B P18089 2/20 0.44
ADRA2C P18825 2/20 0.44
DRD1 P21728 2/20 0.44
DRD4 P21917 2/20 0.44
SLC6A2 P23975 2/20 0.44
HRH2 P25021 2/20 0.44
SLC6A4 P31645 2/20 0.44
HRH1 P35367 2/20 0.44
OPRM1 P35372 2/20 0.44
DRD3 P35462 2/20 0.44
OPRD1 P41143 2/20 0.44
OPRK1 P41145 2/20 0.44
HTR2B P41595 2/20 0.44
HTR6 P50406 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4286221 0.89 HTR2A (0.51) CCR5HTR2AHTR2CHTR1AADRB3
SCHEMBL4278537 0.88 CACNA1B (0.58) CCR5CYP3A4KCNH2CACNA1B
SCHEMBL3485689 0.76 IDO1 (0.53) KDM4EUSP2ALDH1A1LMNACYP3A4
SCHEMBL4282408 0.74 CACNA1B (0.56) HTR2AHTR2CCYP3A4KCNH2CACNA1B
SCHEMBL4277687 0.73 SLC6A4 (0.59) SLC6A2SLC6A4OPRM1OPRK1SLC6A3
SCHEMBL4277656 0.72 CACNA1B (0.59) SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6
SCHEMBL4278578 0.72 CACNA1B (0.59) CYP3A4CACNA1B
SCHEMBL2851104 0.71 CACNA1B (0.44) KDM4EALDH1A1LMNACYP3A4KCNH2
SCHEMBL2851102 0.71 CACNA1B (0.44) KDM4EALDH1A1LMNACYP3A4KCNH2
SCHEMBL4277600 0.71 CACNA1B (0.60) CCR5HTR2AHTR2CHTR1ADRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000174-B2 4-phenylsulfonamidopiperidines as calcium channel blockers PURDUE PHARMA L.P. (US) 2015-04-07 US disclosed
EP-1814851-B1 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO CELTIQUE SA (LU) 2013-06-05 EP disclosed
US-20090105249-A1 4-phenylsulfonamidopiperidines as calcium channel blockers EURO-CELTIQUE S.A. (LU) 2009-04-23 US disclosed
EP-1814851-A2 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2007-08-08 EP disclosed
WO-2006040181-A2 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105249-A1 4-phenylsulfonamidopiperidines as calcium channel blockers CACNA1A, CACNA1E, CACNA1B CCR5 1610/4885HTR2A 1261/4885HTR2C 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.